LIC
TEVA icon

Lodestar Investment Counsel’s Teva Pharmaceuticals TEVA Stock Holding History

Lodestar Investment Counsel’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-6,017
Closed -$277K – 162
2016
Q3 		$277K Sell
6,017
-150
-2% -$7.83K 0.04% 142
2016
Q2 		$310K Buy
6,167
+1,500
+32% +$79.9K 0.04% 136
2016
Q1 		$250K Buy
+4,667
New +$274K 0.04% 149

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Lodestar Investment Counsel's TEVA Position: Q4 2016 in Review

Lodestar Investment Counsel sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 6,017 shares — an estimated $277K sold.

Lodestar Investment Counsel first reported a position in TEVA in Q1 2016 and held it in 3 quarters. The position peaked at $310K in Q2 2016. 738 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

  • Lodestar Investment Counsel reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Lodestar Investment Counsel sold 6,017 Teva Pharmaceuticals shares in Q4 2016, an estimated $277K.
  • Lodestar Investment Counsel first reported a position in Teva Pharmaceuticals in Q1 2016 and held it in 3 quarters.
  • Lodestar Investment Counsel's Teva Pharmaceuticals position peaked at $310K in Q2 2016.
  • 738 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Lodestar Investment Counsel's 13F filing for Q4 2016, filed 23 Jan 2017.